Last reviewed 2026-04-20 · How we verify

Rebif®

Rebif®, marketed by EMD Serono, is a well-established treatment in the multiple sclerosis (MS) market. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and revenue stability. However, the primary risk lies in the increasing competition from newer therapies, which could erode Rebif's market share.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study (PHASE2)
• A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS (PHASE3)
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
• Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients (PHASE2)
• Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis (PHASE3)
• BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (PHASE3)
• Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
• A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.